Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.

Journal of gastroenterology and hepatology - 1 Aug 2015

Ogawa Eiichi, Furusyo Norihiro, Kajiwara Eiji, Nomura Hideyuki, Kawano Akira, Takahashi Kazuhiro, Dohmen Kazufumi, Satoh Takeaki, Azuma Koichi, Nakamuta Makoto, Koyanagi Toshimasa, Kotoh Kazuhiro, Shimoda Shinji, Hayashi Jun

Abstract excerpt

BACKGROUND AND AIM: The addition of hepatitis C virus (HCV) NS3/4A protease inhibitors to the pegylated interferon (PEG-IFN) α and ribavirin combination regimen (triple therapy) has dramatically improved treatment outcome. Unfortunately, anemia remains a common adverse effect. This study was done to compare the development of severe anemia during simeprevir- or telaprevir-based triple therapy. METHODS: This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Glomerular Filtration Rate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemoglobins

Share to Multicenter Studies as Topic

Share to Oligopeptides

Share to Pyrophosphatases

Share to Simeprevir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 25777545
DOI: 10.1111/jgh.12945

Genes

ITPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.PMID 25777545Read ↗

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.Semantic proximity Read ↗

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.Semantic proximity Read ↗

Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.Semantic proximity Read ↗

Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.Semantic proximity Read ↗

ITPA gene variant protects against anemia induced by pegylated interferon‐α and ribavirin therapy for Japanese patients with chronic hepatitis CSemantic proximity Read ↗

ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.Semantic proximity Read ↗

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.Semantic proximity Read ↗

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.Semantic proximity Read ↗

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.Semantic proximity Read ↗

Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.